Free Trial
NASDAQ:BLRX

BioLineRx (BLRX) Stock Price, News & Analysis

BioLineRx logo
$0.55 +0.01 (+1.87%)
(As of 11/20/2024 ET)

About BioLineRx Stock (NASDAQ:BLRX)

Key Stats

Today's Range
$0.52
$0.57
50-Day Range
$0.40
$0.66
52-Week Range
$0.39
$1.89
Volume
362,986 shs
Average Volume
352,431 shs
Market Capitalization
$43.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
39th Percentile Overall Score

BLRX MarketRank™: 

BioLineRx scored higher than 39% of companies evaluated by MarketBeat, and ranked 766th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioLineRx has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioLineRx's stock forecast and price target.
  • Earnings Growth

    Earnings for BioLineRx are expected to decrease in the coming year, from ($0.03) to ($0.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioLineRx is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioLineRx is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioLineRx has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.33% of the outstanding shares of BioLineRx have been sold short.
  • Short Interest Ratio / Days to Cover

    BioLineRx has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioLineRx has recently increased by 70.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioLineRx does not currently pay a dividend.

  • Dividend Growth

    BioLineRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.33% of the outstanding shares of BioLineRx have been sold short.
  • Short Interest Ratio / Days to Cover

    BioLineRx has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioLineRx has recently increased by 70.58%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BioLineRx has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for BioLineRx this week, compared to 1 article on an average week.
  • Search Interest

    9 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioLineRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.10% of the stock of BioLineRx is held by insiders.

  • Percentage Held by Institutions

    Only 1.56% of the stock of BioLineRx is held by institutions.

  • Read more about BioLineRx's insider trading history.
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
BioLineRx Granted Extension to Meet Nasdaq Requirements
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials
BioLine RX Ltd. ADR
See More Headlines

BLRX Stock Analysis - Frequently Asked Questions

BioLineRx's stock was trading at $1.57 at the beginning of the year. Since then, BLRX shares have decreased by 65.3% and is now trading at $0.5452.
View the best growth stocks for 2024 here
.

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings results on Tuesday, May, 28th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.28. The biotechnology company had revenue of $6.86 million for the quarter, compared to the consensus estimate of $0.34 million.

Top institutional investors of BioLineRx include Atria Investments Inc (0.17%).

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA).

Company Calendar

Last Earnings
5/28/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLRX
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+3,751.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-60,610,000.00
Pretax Margin
-176.67%

Debt

Sales & Book Value

Annual Sales
$17.05 million
Book Value
$0.18 per share

Miscellaneous

Free Float
79,060,000
Market Cap
$43.58 million
Optionable
Optionable
Beta
1.48
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:BLRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners